Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 6/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11878002 | 0.77 | PARP1 (0.44) | TSHRPARP1CREBBPBRD4NISCH | |
| SCHEMBL1783171 | 0.77 | MAOB (0.43) | TSHRMAOBMAOAANPEPCYP1A2 | |
| SCHEMBL7664111 | 0.77 | MAOB (0.43) | TSHRMAOBMAOAANPEPCYP1A2 | |
| SCHEMBL8823819 | 0.77 | MAOB (0.39) | TSHRMAOBMAOAANPEPCYP1A2 | |
| SCHEMBL8496949 | 0.77 | MAOB (0.39) | TSHRMAOBMAOAANPEPCREBBP | |
| SCHEMBL20525259 | 0.75 | MAOA (0.38) | TSHRMAOBMAOAANPEPNISCH | |
| SCHEMBL19746 | 0.74 | CYP19A1 (0.45) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL1782335 | 0.74 | MAOB (0.41) | TSHRMAOBMAOAANPEPCYP1A2 | |
| SCHEMBL11733122 | 0.73 | CYP19A1 (0.44) | MAOBMAOAANPEPKDM4EADORA3 | |
| SCHEMBL30292163 | 0.73 | SMN1; SMN2 (0.42) | TSHRMAOBMAOAANPEPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237659-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-09-29 | — | — | US | disclosed |
| EP-2367810-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | Glenmark Pharmaceuticals S.A. (CH) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010055384-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237659-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | TRPV3, TRPV2, TRPV1 | TSHR 1639/4885PARP1 4592/4885MAOB 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.